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The Hdmx gene product is related to the Hdm2 onco-
protein, both of which interact with and regulate p53
stability and function. Like Hdm2, Hdmx is able to in-
hibit p53 transactivation; however, at variance with
Hdm2, which promotes ubiquitination, nuclear export,
and degradation of p53, Hdmx increases p53 stability.
We report here (i) that overexpressed Hdmx is cytoplas-
mic and Hdm2 recruits Hdmx into the nucleus and (ii)
that nuclear Hdmx blocks Hdm2-mediated nuclear ex-
port of p53 and down-regulates p53-dependent tran-
scription. Furthermore we showed that Hdmx inhibits
Hdm2-mediated p53 ubiquitination. It appears, there-
fore, that a regulatory loop exists in which Hdm2 regu-
lates the intracellular localization of Hdmx, and nuclear
Hdmx regulates several functions of Hdm2 (ubiquitin
ligase activity and p53 nuclear export).
p53 is the most frequently inactivated tumor suppressor
gene in human cancer irrespective of the tumor type, site, and
patient age. In cells undergoing DNA damage or responding to
certain forms of stress (replicative senescence, hypoxia, oxida-
tive stress, and oncogene overexpression) the ordinarily short-
lived p53 protein is stabilized, rapidly accumulates, and under-
goes several activating post-translational modifications. In this
context, activated p53, via its ability to regulate gene transcrip-
tion, elicits either a cell cycle arrest or apoptosis (1). As it would
be expected, p53 actions are largely regulated by post-transla-
tional events, including direct binding and occlusion of the
transactivation domain, ubiquitination and degradation by the
proteosome, and control of subcellular localization. The Hdm2
protein has been implicated in all three of these processes, most
recently as mediator of the export of p53 from the nucleus,
which enhances the degradation of p53 in cytoplasmic proteo-
somes (2–5). Hdm2 functions as an E31 ubiquitin ligase for p53,
and the C-terminal RING-finger domain of Hdm2 is critical for
ligase activity (6, 7). Interestingly the Hdm2 gene itself is a
transcriptional target of p53. Thus, there is evidence for an
autoregulatory feedback loop involving the expression and
function of Hdm2 and p53. From a genetic standpoint, the close
relationship between the murine ortholog of Hdm2, Mdm2, and
p53 is further supported by the striking observation that a
p53-null state can completely rescue the early-embryonic-le-
thal phenotype associated with Mdm2 deficiency (8, 9).
Hdmx is structurally related to Hdm2, and a significant
similarity is especially notable in the p53-binding domain and
in the C-terminal RING-finger domain (10). Hdmx has been
shown to bind p53 and inhibit p53 transactivation in specific
cellular contexts but, unlike Hdm2, is unable to induce p53
degradation (10, 11). Similar conclusions were drawn when
using the Hdmx murine ortholog Mdmx (12, 13). Moreover,
Mdmx and Mdm2 form stable heterodimers through their C-
terminal RING-finger domains, and this interaction results in
a substantial increase in the steady-state levels of Mdm2 (14,
15). Finally it has been reported that both Mdmx (13) and
Hdmx (11), through a yet unknown mechanism, are able to
interfere with Mdm2-mediated p53 degradation, resulting in
an increase in p53 protein levels while maintaining suppres-
sion of p53 transactivation. It was therefore proposed that
Hdmx (and Mdmx) secures a nuclear pool of transcriptionally
incompetent p53, which upon stress can be quickly activated.
Finally the first genetic evidences confirming the role of Mdmx
as a critical regulator of p53 function in vivo are now available.
Mdmx-mutant mice die around midgestation because of loss of
cell proliferation, while loss of p53 completely rescues this
embryonic lethality (16).2 These new exciting data raise the
possibility that increased Mdmx levels and the resulting inhi-
bition of p53 transcriptional activity contribute to development
of human tumors.
We show here that exogenous Hdmx is mainly localized in
the cytoplasm of transfected cells by indirect immunofluores-
cence, while when co-expressed with Hdm2, Hdmx was then
found almost exclusively in the nucleus. We show that this
effect is dependent on the integrity of the RING-finger domain
of both Hdmx and Hdm2 proteins. Furthermore, we demon-
strate that the Hdm2-dependent nuclear recruitment of Hdmx
is indispensable for its ability to exert its two previously re-
ported activities, regulation of p53 steady state levels and block
of p53 transcriptional ability.
EXPERIMENTAL PROCEDURES
Plasmids—DNAs encoding wild-type human p53 and Hdm2 in
pCMV and the p53 reporter plasmid pG13Luc were a gift from B.
Vogelstein. The HA-tagged wild-type p53, p53 K305N (nuclear localiza-
tion signal (NLS)) (17), and p53 173L (DNA binding-defective) mutants
were provided to us by K. Maki and K. Vousden; Hdm2 NLS and Hdm2
G58A mutants were obtained from A. Levine. The pcDNA3.1 Myc-
tagged Hdmx constructs (wild type and N-terminal truncation mutant
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(amino acids 101–490), also designated Hdmxp53bs) were described
previously (15) and kindly provided by D. George. Full-length Hdmx
and the N-terminal truncated (amino acids 101–490) Hdmx fragment
were released from the above constructs using a BamHI-XhoI restric-
tion digest and subcloned into the pcDNA3X()MyEGFP to generate
Myc-GFP-tagged Hdmx and Myc-GFP-Hdmx-(101–490). The tagged
Hdmx (R-NLS (amino acids 2–430) and R (amino acids 2–451))
deletion mutants, deleted either of the entire RING-finger region
including the putative NLS or most of it to leave the putative NLS
intact, were generated by PCR amplification of the corresponding
fragments using a 5-primer including a BamHI site and 3-primers
including XhoI sites. The PCR products were subcloned into
pcDNA3.1Myc and pcDNA3X()MyEGFP to generate the Myc-tagged
Hdmx (R-NLS) and the Myc-tagged Hdmx (R), and the Myc-GFP-
tagged Hdmx (R-NLS) and the Myc-GFP-tagged Hdmx (R), respec-
tively. Hdmx NLS mutants (KRPRD 3 ATPLD) were generated
using the QuikChange mutagenesis kit (Stratagene). The following
oligonucleotide and its complement were used for the mutagenesis in
the context of the Myc-tagged Hdmx and Myc-GFP-tagged Hdmx
constructs: 5-tgtgaggcaacaccactagacggg.
Tissue Culture and Immunofluorescence—U2OS, Soas-2, NIH-3T3,
and Phoenix (derived from the 293T cell line) cell lines were grown in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bo-
vine serum, and 100 g/ml penicillin and streptomycin. Transfections
were carried out using the calcium phosphate method or the FuGENE
transfection reagent (Roche Molecular Biochemicals). For immunofluo-
rescence staining, cells were transfected at 80% confluency on glass
coverslips in six-well dishes and fixed 24 h after addition of the DNA
mixtures. Fixed coverslips were washed twice in phosphate-buffered
saline, permeabilized in 0.15% Triton X-100 for 5 min, and incubated in
blocking buffer (phosphate-buffered saline 2% bovine serum albumin)
for 30 min. Cells were than incubated in blocking buffer containing
primary antibody for 1 h as indicated below and then washed exten-
sively in phosphate-buffered saline before incubation with the appro-
priate fluorochrome-conjugated secondary antibody for 1 h. Stained
cells were mounted on glass slides and examined using standard im-
munofluorescence or confocal microscopy. Alexa or Jackson Immunore-
search secondary antibodies were used for confocal or standard micros-
copy, respectively.
Staining of p53 was carried out using the anti-p53 polyclonal FL-393
or anti-p53 monoclonal DO-1 (Santa Cruz Biotechnology), or, to detect
HA-p53, the anti-HA polyclonal antibody HA.11 (Babco) was used.
Mdm2 staining was carried out using the anti-Mdm2 monoclonal anti-
body SMP14 or the polyclonal antibody N20 (Santa Cruz Biotechnolo-
gy). The Myc-tagged Hdmx proteins were detected using an anti-Myc
(9E10) monoclonal or polyclonal (Upstate Biotechnology) antibody
and/or the previously described anti-Hdmx mouse monoclonal antibody
6B1A (11) kindly provided by A. Jochemsen.
Luciferase Assay—U2OS cells were grown on six-well plates and
transfected as outlined above. Luciferase analyses were performed with
a commercial kit (Promega), and activity was measured in a luminom-
eter. To correct for transfection efficiency, 1 g of CMVlacZ was co-
transfected in all cases, and luciferase values were corrected for -ga-
lactosidase activity.
Immunoprecipitation and Western Blotting—Cells were rinsed with
phosphate-buffered saline and scraped in the lysis buffer (50 mM Hepes,
pH 7.5, 150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 2 mM dithiothreitol,
0.1% Tween 20, 1 mM phenylmethylsulfonyl fluoride, 0.4 units/ml apro-
tinin, 10 mM -glycerophosphate, 1 mM NaF, 0.1 mM NaVO4)  10%
glycerol and sonicated 2 7 s (Sonicator, Ultrasonic processor XL, Heat
Systems, 12–14% power). Debris were removed by sedimentation at
4 °C (20 min at 14,000 rpm). For immunoprecipitation assays, cell
lysates (250 g of protein) were incubated with 1–3 g of the appro-
priate antibody (9E10 or SMP14) for 2 h at 4 °C. Following the addition
of 30 l of a protein A-Sepharose beads mixture, the reactions were
incubated for 1 h at 4 °C; the beads were then washed three times in the
lysis buffer and resuspended in 30 l of SDS sample loading buffer. The
immunoprecipitates or the protein extracts (for straight Western blot
analysis) were resolved by SDS-PAGE and transferred to nitrocellulose
membrane (Schleicher & Schuell). The proteins of interest were de-
tected by incubation of the membrane with primary specific antibody as
indicated below in 5% milk followed by a horseradish peroxidase-
conjugated anti-mouse or anti-rabbit antibody and a chemiluminescent
substrate (ECL, Amersham Biosciences, Inc.). The membrane was probed
with either an anti-HA monoclonal antibody (HA.11 from Babco) to detect
the transfected p53 proteins (wild type and K305N) or the anti-p53 mono-
clonal antibody (DO-1). The Mdm2 antibody SMP14 (Santa Cruz Biotech-
nology) was used to detect Hdm2, and an anti-Myc (9E10) monoclonal
antibody was used to detect the Myc-tagged Hdmx proteins.
RESULTS
Hdm2 Recruits Hdmx into the Nucleus—Determination of
the subcellular localization of transfected Hdmx and/or Mdmx
in different cellular contexts has led to conflicting observations
(13, 18–21). To revisit this issue, we determined the localiza-
tion of exogenous Myc-tagged (N-terminal) Hdmx and GFP-
Hdmx in U2OS, Soas-2, and NIH-3T3 cell lines by immunoflu-
orescence. In all cell types analyzed, both Hdmx-tagged
proteins were mainly found in the cytoplasm (Fig. 1, a–d). The
intensity and the frequency of the nuclear staining slightly
varied from one cell line to another but always appeared much
less frequent (5% of cells) and less intense than the cytoplas-
mic staining (Fig. 1h).
Sequence analysis of Hdmx reveals a single putative NLS in
the C-terminal RING-finger domain (KRPRD). Point mutations
in this motif (KTLLD) had no major effect on the cellular
distribution of Hdmx (Fig. 1, e and h). Deletion of the C-
terminal RING domain instead resulted in both nuclear and
cytoplasmic localization of Hdmx (Hdmx R-NLS and R, car-
rying deletions of either the entire RING domain, including the
putative NLS, or most of it to leave the putative NLS intact)
(Fig. 1, f–h). It appears, therefore, that the putative NLS of
Hdmx is not functional and that its C-terminal RING-finger
motif is an important determinant of the cellular distribution of
Hdmx.
Since Hdm2 is a nuclear cytoplasmic shuttling protein (2, 3)
and Mdm2 (the mouse ortholog of Hdm2) forms stable hetero-
oligomers with Mdmx (14, 15), we investigated whether Hdm2
levels affect Hdmx localization. Strikingly, GFP-Hdmx was
entirely nuclear when co-expressed with Hdm2 in U2OS (Fig.
2, c–e and o) or Saos-2 cells (not shown). Similar results were
obtained using a Hdmx-Myc tagged construct (not shown). This
effect did not depend on the ability of Hdm2 to bind p53 since
the p53 binding-defective mutant, Hdm2 G58A (22), was still
able to recruit Hdmx into the nucleus (Fig. 2o).
More importantly this effect depends on the ability of Hdm2
to interact with Hdmx. Indeed, deletion of the RING domains of
Hdm2 (Hdm2R) or Hdmx (Hdmx R and R-NLS) abrogated
their ability to form heterodimers (Fig. 2p) and the nuclear
recruitment of Hdmx by co-expressed Hdm2 (Fig. 2, f–k and o).
Moreover, the putative NLS motif of Hdmx appears to be
dispensable for its recruitment into the nucleus (Fig. 2o),
whereas this effect is dependent on the integrity of the Hdm2
NLS (Fig. 2, l–n and o) (3) further supporting that the observed
effect on Hdmx localization is mediated by a direct interaction
with Hdm2.
Since p53 binds Hdmx and possesses a nuclear cytoplasmic
shuttling activity independent of Hdm2 (23, 24), we tested
whether p53 can also recruit Hdmx in the nucleus. As shown,
overexpression of wild-type p53 had a minor, yet reproducible,
delocalization effect on Hdmx (Fig. 2o). Expression of a p53
DNA binding-defective mutant (173L) was unable to alter the
Hdmx localization pattern (Fig. 2o), thus suggesting that the
slight nuclear accumulation of Hdmx following p53 overexpres-
sion is caused by the increased expression of a p53 target gene.
Based on the data above, we propose that this effect is medi-
ated by the transcriptional activation of endogenous Hdm2.
Hdmx Increases Hdm2 Protein Levels and Inhibits Hdm2-
mediated p53 Ubiquitination—It is generally accepted that
Hdm2-mediated ubiquitination of p53 is essential for its deg-
radation. Since binding of both Mdmx and Hdmx to Mdm2
increases the steady-state level of Mdm2 without affecting p53
stability (13, 15), one obvious possibility is that Hdmx binding
inhibits the Hdm2 E3 ligase function. This is supported by the
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finding that Hdmx contacts Hdm2 in its RING-finger domain,
a region essential for its ubiquitin ligase activity (6, 7).
We therefore investigated the levels of p53 ubiquitination in
the presence of overexpressed Hdm2 and Hdmx by immuno-
blotting analysis (Fig. 3). As expected, overexpressed Hdm2
promoted ubiquitination of endogenous p53. This effect was
dose-dependent (Fig. 3, lanes 2 and 3) and based on the ability
of Hdm2 to bind p53 (G58A mutant, Fig. 3, lane 4). Expression
of Hdmx instead had no measurable effect on p53 ubiquitina-
tion (Fig. 3, lane 5), indicating that Hdmx by itself does not
have ubiquitin ligase activity toward p53. Co-transfection of
Hdmx and Hdm2 resulted in stabilization of the Hdm2 protein,
as expected, that was dependent on the integrity of the Hdmx
RING domain (Fig. 3, compare lanes 2 with 6, 7 and 2 with 8,
9). In these conditions, Hdmx did not detectably change the
overall pattern of Hdm2-dependent ubiquitination of p53. How-
ever, in evaluating the effect of Hdmx on Hdm2-dependent p53
ubiquitination, one should consider the property of Hdmx to
increase the protein levels of Hdm2. To this end, we set up
experimental conditions that allowed the same amount of
Hdm2 protein to be expressed even in the presence of increas-
ing Hdmx protein concentrations (Fig. 3, lanes 10 and 11).
Under these conditions, a significant reduction of p53 ubiquiti-
nation was observed in the presence of high Hdmx protein
levels. Notably, expression of the HdmxR mutant did not
significantly interfere with Hdm2-mediated p53 ubiquitination
(Fig. 3, lanes 8 and 9). Similar results were obtained analyzing
the status of ubiquitination of exogenous p53 in different cel-
lular contexts such as in U2OS, Soas-2, and p53xMdm2 knock-
out murine embryonic fibroblasts (HA-p53) (not shown). To-
gether these data indicate that Hdmx has the potential to
inhibit Hdm2 ligase activity. However, the concomitant ability
of Hdmx to stabilize the Hdm2 protein suggests that, under
physiological conditions, inhibition of the Hdm2 ligase activity
by Hdmx is not sufficient to account for the inhibition of Hdm2-
mediated p53 degradation by Hdmx.
Hdmx Blocks Hdm2-mediated Nuclear Export of p53—It is
well documented that wild-type p53 must reach the cytoplasm
to be efficiently degraded (2, 4, 5, 24, 25). An alternative ex-
planation for the stabilization of p53 is, therefore, that Hdmx
interferes with the Hdm2-dependent p53 nuclear export. To
test this possibility, we investigated the reciprocal effects of
Hdm2, Hdmx, and p53 on their subcellular localization.
Overexpressed p53 was almost exclusively nuclear and,
when expressed with Hdm2, was partly relocalized to the cy-
toplasm as expected (4, 5) (Fig. 4, a–f and s). Strikingly, co-
expression of Hdmx inhibited the Hdm2-induced cytoplasmic
delocalization of p53 (Fig. 4, g–j and s), indicating that nuclear
Hdmx can block the Hdm2-dependent nuclear export of p53.
p53 export, however, was not efficiently perturbed by Hdmx
when co-expressed with the Hdm2 NLS mutant. Importantly
we have shown earlier that the nuclear recruitment of Hdmx by
Hdm2 NLS is only partial. Mutants of Hdmx unable to bind
Hdm2, such as Hdmx R and R-NLS, were incapable of revers-
ing the Hdm2-induced export of p53 (Fig. 4, k–n and s) even if
a significant fraction of these mutants are found in the nucleus
(see also Fig. 1, f–h). Together these observations indicate that
the nuclear localization of Hdmx is necessary but not sufficient
to reverse Hdm2-induced nuclear export and that this effect is
dependent on the ability of Hdmx to interact with Hdm2.
Finally it has been shown that nuclear export of p53 is not
required for its ubiquitination and that a p53 cytoplasmic mu-
tant (K305N) can be ubiquitinated and degraded by Hdm2 NLS
(26). Our data suggest that stabilization of p53 by Hdmx is the
consequence of its ability to block p53 nuclear export. There-
fore, Hdmx should be unable to reverse the Hdm2-dependent
FIG. 1. Cellular localization of exogenous Hdmx wild type and
mutants in NIH-3T3, Saos-2, and U2OS cells. a–c, U2OS, Saos-2,
and NIH-3T3 cells were transfected with a plasmid expressing Myc-
tagged Hdmx wild type alone. d–g, U2OS cells were transfected with a
plasmid expressing GFP-Hdmx wild type (d), an NLS mutant (e), and
two C-terminal truncated mutants, R (f) and R-NLS (g). After 24 h,
cells were fixed and stained for Hdmx (red) using the anti-Myc mono-
clonal antibody 9E10 (a–c) by indirect immunofluorescence. Cells were
examined for Cy3 fluorescence (a–c) and for GFP-Hdmx fluorescence
(green) (d–g). DNA (blue) is stained with 4,6-diamidino-2-phenylindole
(a–g). h, the Hdmx staining pattern in cells (Saos-2 and U2OS) trans-
fected with the indicated Hdmx constructs was scored for more than 100
cells in two separate experiments; values are means  S.D. Cells were
scored as having fluorescence exclusively in the nucleus (N) that was
stronger in the nucleus (N/{C}), equal in the nucleus and cytoplasm
(N/C), or stronger in the cytoplasm ({N}/C  C).
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degradation of cytoplasmic p53. To test this hypothesis, we
examined the levels of p53 and p53(K305N) following overex-
pression of Hdm2 or Hdm2 NLS, either alone or in the presence
of Hdmx, in the U2OS (Fig. 5, a and b) or Soas-2 cells and in the
p53xMdm2 knockout murine embryonic fibroblasts. In the ab-
sence of Hdmx, Hdm2 and Hdm2 NLS induced ubiquitination
(not shown) and subsequent degradation of p53 or p53(K305N),
respectively. However, co-expression of Hdmx appeared to sta-
bilize wild-type p53 but had no effect on the p53 cytoplasmic
mutant, indicating that the ability of Hdmx to inhibit Hdm2
function is restricted to the nuclear pool of Hdmx. In contrast,
Hdmx expression resulted in the stabilization of both Hdm2
and Hdm2 NLS. This last observation suggests that the Hdmx-
dependent stabilization of Hdm2 and p53 are achieved through
different mechanisms.
Nuclear Hdmx Down-regulates p53-dependent Transcrip-
tion—Overexpression of Hdmx results in a modest, yet consist-
ent, decrease of the p53 transcriptional regulation ability (11–
13, 20). At first analysis, this effect of Hdmx on p53-dependent
transcription contrasts with our observation that overex-
FIG. 2. Cellular redistribution of exogenous Hdmx wild type
and mutants upon Hdm2 or p53 co-expression. a–f, U2OS cells
were transfected with a plasmid expressing GFPHdmx (a) and Hdm2
(b) wild type alone or with plasmids expressing GFPHdmx and Hdm2
(c–e), GFPHdmx and Hdm2R (f–h), GFPHdmxR and Hdm2 (i–k), or
GFPHdmx and Hdm2 NLS (l–n). After 24 h, cells were fixed and stained
FIG. 3. Effects of Hdmx on Mdm2-mediated p53 ubiquitination.
Phoenix cells were transfected with DNAs encoding Hdm2 wild type
and mutants alone (lanes 2, 3, and 4) or in the presence of either
Myc-GFPHdmx wild type (lanes 6, 7, 10, and 11) or Myc-GFPHdmxR
(lanes 8 and 9). Cells were also transfected with DNA expressing Myc-
GFPHdmx alone (lane 5). The amount of DNA (g) transfected is
indicated. Lanes 1 correspond to nontransfected cells. The protein ex-
tracts were prepared 24 h later and examined by immunoblot analysis
with the p53 monoclonal antibody DO-1. The ladder of bands indicated
is endogenous ubiquitinated p53 ((Ub)n-p53). Hdm2 and Hdmx protein
levels were monitored in the transfected cells by stripping the blot and
reprobing with the Mdm2 monoclonal antibody SMP14 and the anti-
Myc monoclonal antibody 9E10.
for Hdm2 (red) using the anti-Mdm2 monoclonal antibody SMP14 by
indirect immunofluorescence. Cells were examined for Cy3 fluorescence
and for GFP-Hdmx fluorescence (green). DNA (blue) is stained with
4,6-diamidino-2-phenylindole. o, the GFPHdmx pattern in U2OS cells
transfected with the indicated GFPHdmx, Hdm2, and p53 constructs
was scored for more than 100 cells in three separate experiments;
values are means  S.D. Cells were scored as having fluorescence
exclusively in the nucleus (N), stronger in the nucleus (N/{C}), equal in
the nucleus and cytoplasm (N/C), or stronger in the cytoplasm ({N}/C 
C). Only cells expressing both Hdmx and Hdm2 proteins were consid-
ered for the analysis. (For I, 0.5 g of GFPHdmx was transfected with
0.25 g of Hdm2, and for all the other transfection conditions, 0.5 g of
GFPHdmx-expressing constructs was transfected with 1 g of Hdm2- or
p53-expressing constructs.) p, co-immunoprecipitation of Hdmx species
with wild-type or mutant Hdm2 proteins. Lysates from U2O cells trans-
fected with the indicated constructs were treated with anti-Myc anti-
body (9E10) and protein A beads. Immunoprecipitates were analyzed by
Western blotting using anti-Hdm2 antibody (upper panel). Comparable
Hdmx and Hdm2 transfection efficiencies were confirmed by Western
blotting of lysate samples using anti-Myc antibody (middle panel) and
anti-Hdm2 antibody (lower panel). The Hdm2 protein levels are in-
creased in the presence of wild-type Hdmx. Ip, immunoprecipitation.
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pressed Hdmx is mainly localized to the cytoplasm. However,
in all reported experiments but one (12), the effect of Hdmx was
investigated by transient transfection using various p53-defi-
cient cell lines (Hep3B, H1299, Calu, and p53/ murine em-
bryonic fibroblasts), overexpressed p53, and various reporter
constructs (14, 15). In these experimental conditions, overex-
pressed p53 might trigger recruitment of Hdmx into the nu-
cleus indirectly through its effect on the endogenous Hdm2
promoter. To test this possibility, we have transfected U2OS
cells, which express endogenous p53, with the reporter con-
struct pG13Luc containing 13 copies of the p53 consensus se-
quence upstream of a minimal promoter driving transcription
of the luciferase gene. As expected, endogenous p53 is able to
sustain a significant basal level of expression of the reporter
construct (Fig. 6). Overexpression of Hdm2, but not of Hdmx,
significantly inhibited pG13Luc transcription. Expression of
HdmxR, which is partly localized in the nucleus (see Fig. 1, f
and h), slightly, yet reproducibly, reduced the p53 transcrip-
tional ability. Strikingly, simultaneous expression of Hdm2
and Hdmx resulted in an almost complete repression of p53
pG13Luc transcription. These findings demonstrate that regu-
lation of Hdmx by Hdm2 is an absolute requirement for the
efficient regulation of p53 activity by Hdmx and suggest that
only the nuclear fraction of Hdmx regulates p53-dependent
transcription.
DISCUSSION
We have shown here that exogenous Hdmx, when expressed
alone, is mainly cytoplasmic, while, in the presence of Hdm2, it
becomes mainly nuclear. Nuclear relocalization of Hdmx by
overexpressed Hdm2 depends on their reciprocal interaction as
FIG. 4. Hdm2 does not relocalize p53 in the presence of Hdmx.
a–r, U2OS cells were transfected with a plasmid expressing p53 alone
(a–c) or with plasmids expressing p53 and Hdm2 (d–f); p53, Hdm2, and
GFPHdmx (g–j); p53, Hdm2, and GFPHdmxR (k–n); or p53, Hdm2R,
and GFPHdmx (o–r). After 24 h, cells were fixed and stained for p53
(red) Hdm2 (blue) using the anti-p53 polyclonal antibody FL393 and the
anti-Mdm2 monoclonal antibody SMP14 by indirect immunofluores-
cence. Cells were examined for Cy3 and Alexa (blue) fluorescence and
for GFP-Hdmx fluorescence (green). s, the staining pattern for p53 in
U2OS cells expressing the indicated GFPHdmx, Hdm2, and p53 con-
structs were scored for more than 100 cells in three separate experi-
ments; values are means  S.D. Cells were scored as described in Fig.
2o. Only cells expressing the three proteins were considered for the
analysis. Hdmx does not prevent Hdm2NLS-induced p53(K305N) deg-
radation. Dapi, 4,6-diamidino-2-phenylindole.
FIG. 5. Hdmx does not reverse Hdm2NLS-mediated degrada-
tion of cytoplasmic p53(K305N). a, U2OS cells were transfected with
2 g of HA-p53 alone or together with 5 g of Hdm2 in the absence or
presence of either 5 g of Myc-GFPHdmx or 5 g of Myc-GFPHdmxR.
b, U2OS cells were transfected with 2 g of HA-p53(K305N) alone or
together with 5 g of Hdm2NLS in the absence or presence of either 5
g of Myc-GFPHdmx or 5 g of Myc-GFPHdmxR, all in combination
with 1 g of Myc-EGFP. Cell lysates were analyzed by immunoblot
analysis with the anti-HA monoclonal antibody (HA.11) to detect p53
levels, with the anti-Hdm2 SMP14 antibody to detect the Hdm2 pro-
teins, and with the anti-Myc antibody (9E10) to detect the Hdmx pro-
teins. Equal transfection efficiencies were confirmed using the anti-Myc
antibody (9E10) for the detection of Myc-EGFP.
FIG. 6. Hdm2-dependent nuclear recruitment of Hdmx is nec-
essary for efficient inhibition of p53 transcriptional activity.
U2OS cells were transfected with 400 ng of the p53 reporter construct
(pG13Luc) and DNAs expressing Hdm2 wild type and p53 binding-
defective mutant G58A (300 ng), GFP-Hdmx wild type, p53 binding-
defective mutant (Hdmxp53bs), and RING domain-deleted mutant
(HdmxR) alone (800 ng) or a combination of both wild-type proteins as
outlined in the transfection scheme. Luciferase activity is shown as -fold
induction compared with no transfection of the reporter with the S.D. of
triplicates.
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suggested by the finding that this phenomenon requires the
integrity of the RING domain of both proteins. Surprisingly,
however, RING mutants of Hdmx (R and R-NLS) were found
in both the nucleus and cytoplasm even when expressed alone
suggesting that Hdmx binds other cellular factor(s) that might
sequester Hdmx in the cytoplasm in the absence of Hdm2.
Since Hdm2 binds Hdmx in the same RING-finger region, it
might compete for binding and displace this putative interac-
tion. Alternatively, formation of Hdmx oligomers might occur
in the cytoplasm and inhibit the nuclear import of Hdmx by, for
instance, masking its putative NLS, which is located in the
RING-finger motif of the protein. In this context, Hdm2, which
forms stable heterodimers with Hdmx (14), might disrupt the
formation of Hdmx oligomers.
We then investigated the mechanisms by which nuclear
Hdmx inhibits Hdm2-induced p53 degradation. Since this ef-
fect was previously reported to be mediated by the Hdmx
RING-finger and to involve hetero-oligomerization with the
Hdm2 RING-finger, we hypothesized that Hdmx inhibits the
ubiquitin ligase activity of Hdm2. Our data, however, are not
entirely consistent with this model. Indeed, as it was demon-
strated earlier for p19ARF (27), we showed that the interaction
with Hdmx reduces the ubiquitin ligase activity of Hdm2. How-
ever, this effect is counteracted in vivo by the ability of Hdmx
to stabilize Hdm2 suggesting that Hdmx stabilizes p53 through
other mechanisms. And in fact, Hdmx is able to rescue Hdm2-
mediated degradation even in those experimental conditions
where the overall levels of p53 ubiquitination are not affected
by Hdmx. The block of the Hdm2 ligase activity by Hdmx might
instead explain the stabilization of Hdm2 following Hdmx over-
expression. In fact, Hdm2 is not only a ubiquitin protein ligase
for p53 but also mediates its own ubiquitination and stabiliza-
tion (6).
It is believed that the nuclear export of p53 is critical for
efficient Hdm2-mediated degradation, although the function of
Hdm2 in p53 nuclear export is still a matter of debate. We have
demonstrated that Hdmx antagonizes Hdm2-dependent p53
relocalization, thereby providing a simple model for the ability
of Hdmx to stabilize p53. However, the mechanisms through
which Hdmx inhibits nuclear export of p53 by Hdm2 remain
elusive. It has been shown that mutation of the Hdm2 RING-
finger impairs the ubiquitination and cytoplasmic relocaliza-
tion of p53, suggesting that ubiquitin ligation is a crucial signal
for p53 export (4, 5). Considering the modest effect of Hdmx on
Hdm2-induced p53 ubiquitination, Hdmx must exert its stabi-
lization function more downstream by counteracting the relo-
calization effect of the ubiquitination signal. Hdmx forms a
ternary complex with Hdm2 and p53 (11) and could, for in-
stance, occlude the C-terminal p53 nuclear export signal. This
signal has, indeed, been proposed to be indispensable for
Hdm2-mediated p53 export (4, 5). Alternatively, overexpressed
Hdmx might compete with Hdm2 for p53 binding. This possi-
bility, however, appears unlikely since Hdmx does not signifi-
cantly disturb binding of Hdm2 to p53 in co-immunoprecipita-
tion experiments (11).2
Finally we confirmed that Hdmx antagonizes p53 transcrip-
tional activity and demonstrated that nuclear recruitment of
Hdmx is essential for its ability to suppress efficiently p53
transactivation. Indeed, in our experimental setting, the effect
of Hdmx on p53-dependent transcription was marginal when
expressed alone, while it became dramatic when co-expressed
with Hdm2. The mechanism for this suppression is unknown.
The formation of a trimeric complex could block crucial inter-
actions with proteins of the transcriptional machinery.
The biological significance of these particular functions of
Hdmx, however, remains to be elucidated. Recent reports, in-
cluding observations presented here, indicate that stabilized
p53 protein is not able to activate transcription, and it was
proposed that Hdmx secures the presence of a pool of inactive
p53 that can be instantly activated when needed. Overex-
pressed Hdmx, however, is an artificial situation, and it is not
known whether or not it corresponds to any physiological sit-
uations. Indeed, Hdmx protein levels seem to be very low in all
primary cells tested. On the other hand, increased Hdmx levels
were found in a significant fraction of tumor cell lines when
compare with normal cells (28). In general Hdmx expression in
these tumor cell lines correlates with the presence of wild-type
p53, suggesting that deregulated expression of Hdmx plays a
role in carcinogenesis as an alternative way to inactivate p53.
High levels of Hdmx may also explain the efficient response to
radiation and chemotherapy displayed by a subset of tumors,
including germ-cell tumors, which express high levels of wild-
type p53 and Hdm2 (29, 30). The now available mouse models
further support the notion that, at least during embryogenesis,
the primary function of Hdmx is to inhibit p53 function (16).2
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